Johnson, Jared L. http://orcid.org/0000-0003-1802-6527
Yaron, Tomer M. http://orcid.org/0000-0001-6574-7314
Huntsman, Emily M.
Kerelsky, Alexander
Song, Junho http://orcid.org/0000-0003-0898-8749
Regev, Amit
Lin, Ting-Yu
Liberatore, Katarina
Cizin, Daniel M.
Cohen, Benjamin M.
Vasan, Neil
Ma, Yilun
Krismer, Konstantin http://orcid.org/0000-0001-8994-3416
Robles, Jaylissa Torres http://orcid.org/0000-0002-7353-0518
van de Kooij, Bert
van Vlimmeren, Anne E. http://orcid.org/0000-0003-0379-4945
Andrée-Busch, Nicole
Käufer, Norbert F.
Dorovkov, Maxim V. http://orcid.org/0000-0002-1128-1480
Ryazanov, Alexey G.
Takagi, Yuichiro http://orcid.org/0000-0002-0988-6798
Kastenhuber, Edward R. http://orcid.org/0000-0002-1872-212X
Goncalves, Marcus D. http://orcid.org/0000-0002-0784-9248
Hopkins, Benjamin D.
Elemento, Olivier
Taatjes, Dylan J. http://orcid.org/0000-0003-4444-5688
Maucuer, Alexandre http://orcid.org/0000-0003-2947-6654
Yamashita, Akio
Degterev, Alexei http://orcid.org/0000-0002-8240-7132
Uduman, Mohamed
Lu, Jingyi
Landry, Sean D. http://orcid.org/0000-0002-6242-2300
Zhang, Bin
Cossentino, Ian http://orcid.org/0000-0002-1179-2045
Linding, Rune
Blenis, John http://orcid.org/0000-0003-3622-2337
Hornbeck, Peter V.
Turk, Benjamin E. http://orcid.org/0000-0001-9275-4069
Yaffe, Michael B. http://orcid.org/0000-0002-9547-3251
Cantley, Lewis C. http://orcid.org/0000-0002-1298-7653
Article History
Received: 1 May 2022
Accepted: 17 November 2022
First Online: 11 January 2023
Change Date: 3 February 2023
Change Type: Update
Change Details: In the version of Supplementary Table 2 originally published with this article, data on the “ser_thr_all_raw_matrices” sheet were mistakenly arranged by columns rather than rows, and are now correctly transposed in the revised Supplementary Table 2 accompanying this article.
Competing interests
: L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals; is listed as an inventor on a patent (WO2019232403A1, Weill Cornell Medicine) for combination therapy for PI3K-associated disease or disorder, and the identification of therapeutic interventions to improve response to PI3K inhibitors for cancer treatment; is a co-founder and shareholder in Faeth Therapeutics; has equity in and consults for Cell Signaling Technologies, Volastra, Larkspur and 1 Base Pharmaceuticals; and consults for Loxo-Lilly. M.B.Y receives research support from Cardiff Oncology. T.M.Y. is a co-founder and stockholder and is on the board of directors of DESTROKE, an early-stage start-up developing mobile technology for automated clinical stroke detection. J.L.J has received consulting fees from Scorpion Therapeutics and Volastra Therapeutics. O.E. is a founder and equity holder of Volastra Therapeutics and OneThree Biotech; is a member of the scientific advisory board of Owkin, Freenome, Genetic Intelligence, Acuamark and Champions Oncology; and receives research support from Eli Lilly, Janssen and Sanofi. D.J.T. is a member of the scientific advisory board at Dewpoint Therapeutics. A.D. is an equity holder of Denali Therapeutics; and receives research support from Interline Therapeutics. N.V. reports consulting activities for Novartis and is on the scientific advisory board of Heligenics. M.D.G. is a co-founder and shareholder of Faeth Therapeutics, which is developing dietary and pharmacological therapies for cancer; and has received speaking and/or consulting fees from Pfizer, Novartis, Scorpion Therapeutics and Faeth Therapeutics.